Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cortivazol→

Cortivazol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
1110-40-3
Molecular formula
C32H38N2O5
Molecular weight
530.7 g/mol
Drug class
Synthetic glucocorticoidhigh-potency corticosteroid receptor agonist
Mechanism of action
Activates glucocorticoid receptors, suppressing inflammatory gene expression, cytokine production and immune-cell activity. The depot formulation and route determine local versus systemic exposure.
Indications / reported uses
  • Local corticosteroid therapy for selected inflammatory and rheumatic disorders using authorised intra-articular or other local injection products in countries where cortivazol is available; not a general oral systemic corticosteroid indication

Sources: NLM MeSH — Cortivazol · PubMed — Cortivazol glucocorticoid pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cortivazol Environmental Risk Assessment (ERA) (the Cortivazol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.